CJC-1295 + Ipamorelin Blend: The GH Stack
Dual-pathway growth hormone activation through combined GHRH and GHRP signalling for potentially synergistic GH release.
Quick Reference
| Composition | 5mg CJC-1295 (No DAC) + 5mg Ipamorelin |
|---|---|
| Research Dosage | 100-300mcg of each per administration |
| Frequency | 1-3 times daily |
| Administration | Subcutaneous injection |
| Best Timing | Pre-sleep, morning (fasted), post-exercise |
| Reconstitution | 2-3mL bacteriostatic water (acetic water can help) |
| Storage | Refrigerate after reconstitution, use within 4-6 weeks |
The combination of CJC-1295 (No DAC) and Ipamorelin – universally known as "CJC + Ipa" – is the most widely used growth hormone peptide combination in research. These peptides work through entirely different receptor systems, potentially producing synergistic GH release that exceeds what either achieves alone.
This pre-blended formulation provides both peptides in an accurate 1:1 ratio for convenient research, eliminating the need for separate reconstitution and mixing while ensuring precise dosing of each component.
Why Combine CJC-1295 and Ipamorelin?
Two Pathways, One Goal
The combination activates both primary GH-releasing pathways simultaneously:
CJC-1295 (No DAC) – GHRH Pathway
- Binds GHRH receptors on pituitary somatotrophs
- Signals pituitary to synthesise and release GH
- Functions like pressing the "release GH" button
- Activates adenylyl cyclase → cAMP → protein kinase A
Ipamorelin – Ghrelin/GHS Pathway
- Binds ghrelin receptors (GHS-R1a) on the same cells
- Amplifies the GH release signal
- Functions like turning up the volume
- Activates phospholipase C → calcium signalling
Combined Effect
When both signals arrive at pituitary somatotrophs simultaneously:
- Intracellular signals converge on the same cells
- Calcium release is amplified
- GH granule release is enhanced
- Research suggests synergistic effect exceeding simple addition
Why Ipamorelin Specifically?
Ipamorelin is the most selective GHRP available:
- No cortisol increase (unlike GHRP-6, GHRP-2, Hexarelin)
- No prolactin increase
- Minimal appetite effects
This selectivity means cleaner research results without confounding hormonal changes.
Why the No DAC Version?
CJC-1295 without DAC has approximately 30 minute half-life, coordinating perfectly with Ipamorelin's timing:
- Both peptides administered together
- Both active simultaneously
- Coordinated GH pulse
- Returns to baseline between doses
- Mimics natural pulsatile GH release
The DAC version (6-8 day half-life) creates sustained elevation rather than coordinated pulses, which is a different research paradigm.
Research Applications
Growth Hormone Research
- Synergistic GH release through dual pathway activation
- Pulsatile GH patterns mimicking natural physiology
- IGF-1 elevation studies
- GH secretagogue pharmacology
Body Composition Research
- Lean mass effects of elevated GH
- Fat metabolism studies
- Age-related body composition changes
Recovery Research
- Sleep quality and GH relationship
- Tissue repair with elevated GH
- Post-exercise recovery
Dosage Information
Research Dosages
Dosages commonly referenced in literature range from 100-300mcg of each peptide per administration (200-600mcg total blend).
Frequency: 1-3 times daily
Timing Protocols
Pre-sleep (Most Common):
- Aligns with natural nocturnal GH surge
- GH primarily released during deep sleep
- Typical timing: 30-60 minutes before bed
Morning (Fasted):
- Fasted state optimises GH release
- Food blunts GH response
- Typical timing: Upon waking, before eating
Post-Exercise:
- May enhance exercise-induced GH
- Typical timing: Within 30 minutes of training
Multiple Daily Doses:
- Creates multiple GH pulses
- Common protocols: Morning + pre-sleep, or morning + post-workout + pre-sleep
Reconstitution Guide
Note: GHRH peptides (the CJC-1295 component) can dissolve more slowly than other peptides.
Tips for Successful Reconstitution
- Allow vial and water to reach room temperature (approximately 1 hour)
- Consider using 50/50 bacteriostatic water and acetic water (improves CJC dissolution)
- Add 2-3mL to vial, directing stream down inside wall – do not spray directly onto powder
- Do not shake – allow natural dissolution (may take 5-10 minutes)
- Gentle swirling is acceptable if needed
- Refrigerate immediately at 2-8°C once dissolved
Concentration Reference
10mg total vial + 2mL water:
- Total concentration: 5mg/mL (2.5mg/mL each peptide)
- 200mcg each (400mcg total) = 8 units (0.08mL)
- 300mcg each (600mcg total) = 12 units (0.12mL)
Storage Guidelines
Lyophilised (Powder) Form
- Refrigeration (2-8°C) maintains stability for 12+ months
- Freezing (-20°C) extends stability to 24+ months
- Protect from light and moisture
- Keep vial sealed until ready for reconstitution
Reconstituted Solution
- Must be refrigerated at 2-8°C
- Stable for 4-6 weeks when stored correctly
- Do not freeze after reconstitution – freezing can damage peptide structure
- Avoid repeated temperature fluctuations
- Use sterile technique when drawing doses to prevent contamination
- If solution becomes cloudy or contains particles, discard and reconstitute a fresh vial
Frequently Asked Questions
Common questions about CJC-1295 + Ipamorelin Blend research
What is the CJC + Ipa stack?
CJC + Ipa is shorthand for CJC-1295 (No DAC) combined with Ipamorelin. This combination activates both GHRH and ghrelin receptor pathways simultaneously, potentially producing synergistic GH release that exceeds what either peptide achieves alone.
Does this blend use CJC-1295 with DAC or without DAC?
This blend uses CJC-1295 without DAC (also known as Mod GRF 1-29). The No DAC version has approximately 30 minute half-life, which coordinates perfectly with Ipamorelin for pulsatile GH release that mimics natural physiology.
What ratio is used in this blend?
The blend uses a 1:1 ratio with 5mg of each peptide (10mg total). This is the standard research ratio used in published literature examining combined GHRH/GHRP administration.
Why use a pre-blended formulation instead of separate vials?
Pre-blended formulations offer several advantages: guaranteed accurate ratio between components, single reconstitution step, fewer handling steps reducing contamination risk, and overall research convenience. The peptides are stable when combined in lyophilised form.
When is the best time to administer the blend?
Pre-sleep administration is most common as it aligns with the natural nocturnal GH surge. Morning fasted administration and post-exercise timing are also used in research. Multiple daily doses (morning + pre-sleep or morning + post-workout + pre-sleep) create multiple GH pulses throughout the day.
Is the combination more effective than either peptide alone?
Research suggests dual pathway activation produces greater GH release than either pathway alone. CJC-1295 activates GHRH receptors while Ipamorelin activates ghrelin receptors – both signals converge on the same pituitary cells, creating amplified GH release through different intracellular mechanisms.
Why is Ipamorelin chosen over other GHRPs?
Ipamorelin is the most selective growth hormone releasing peptide. Unlike GHRP-6, GHRP-2, and Hexarelin, Ipamorelin does not increase cortisol or prolactin levels and has minimal appetite-stimulating effects. This selectivity provides cleaner research results without confounding hormonal changes.
Does food affect the blend's effectiveness?
Yes. Food, particularly carbohydrates and fats, can blunt the GH response to secretagogue peptides. Research protocols typically administer the blend in a fasted state – at least 2 hours after eating and 30-60 minutes before any food intake.
What are the storage requirements for the reconstituted blend?
Reconstituted solution must be refrigerated at 2-8°C and is stable for 4-6 weeks. Do not freeze after reconstitution. Lyophilised (powder) form is stable refrigerated for 12+ months or frozen for extended storage.
The Science: Dual Pathway Activation
How the Pathways Converge
Both CJC-1295 and Ipamorelin act on the same pituitary somatotroph cells, but through different receptor systems that converge at the level of GH release.
GHRH Receptor Pathway (CJC-1295)
- CJC-1295 binds GHRH receptor
- G-protein (Gs) activation
- Adenylyl cyclase activation
- cAMP increase
- Protein kinase A (PKA) activation
- GH gene transcription
- GH release from granules
GHS Receptor Pathway (Ipamorelin)
- Ipamorelin binds GHS-R1a receptor
- G-protein (Gq) activation
- Phospholipase C activation
- IP3 and DAG production
- Calcium release from internal stores
- GH granule release
Point of Convergence
Both pathways converge at the level of:
- Intracellular calcium: Required for granule release
- GH granule exocytosis: The actual release event
- Gene transcription: Long-term GH production capacity
When both signals arrive simultaneously, the cell receives "double instructions" to release GH, resulting in amplified output.
Why Pulsatile Release Matters
Natural GH secretion is pulsatile – released in bursts, not continuously. This pulsatility:
- Carries biological information (amplitude, frequency)
- May be important for maintaining receptor sensitivity
- Differs fundamentally from sustained elevation
The CJC + Ipa combination produces discrete pulses (due to the No DAC version's short half-life), preserving this natural pattern rather than creating continuous elevation.
Technical Specifications
| CJC-1295 (No DAC) | 5mg |
|---|---|
| Ipamorelin | 5mg |
| Total Content | 10mg |
| Ratio | 1:1 |
| CJC-1295 Molecular Weight | 3367.9 Da |
| Ipamorelin Molecular Weight | 711.85 Da |
| CJC-1295 Target | GHRH Receptor |
| Ipamorelin Target | GHS-R1a Receptor |
| CJC-1295 Half-Life | ~30 minutes |
| Ipamorelin Selectivity | High (no cortisol/prolactin effects) |
| Appearance | White lyophilised powder |
| Purity | ≥99% each component (HPLC verified) |
Quality: Australian University Testing
Why Peptide Quality Matters
The research peptide market contains products of highly variable quality. Independent testing of products from various suppliers has revealed significant issues:
- Purity levels as low as 50% in products claiming "99% purity"
- Incorrect amino acid sequences (entirely wrong peptides)
- Truncated sequences (missing amino acids)
- Bacterial endotoxin contamination
- Oxidised or degraded peptides with reduced activity
Our Testing Protocol
Every batch of CJC-1295 + Ipamorelin Blend from PurposeLabs undergoes comprehensive testing at a leading proteomics laboratory based at an Australian university in Sydney – one of Australia's premier analytical facilities.
Confirms purity levels of ≥99%, identifies any impurities or degradation products.
Verifies exact molecular weight, confirms correct amino acid sequence.
Determines actual peptide content versus salt, moisture, and counter-ions.
Why Australian University Testing?
Our testing partner is an established, verifiable proteomics facility at a major Australian university, with published research credentials, transparent methodology, and no commercial conflict of interest. This contrasts with overseas "certificates of analysis" from unknown or unverifiable laboratories.
Shop CJC-1295 + Ipamorelin Blend
Australian university tested. 99%+ purity verified by HPLC and mass spectrometry. Fast shipping from Sydney.
| Product | Size | Price |
|---|
References
Key studies for researchers seeking primary literature:
- Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology, 1998.
- Alba M, et al. "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse." American Journal of Physiology, 2006.
- Ionescu M, Bhopale GM. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295." Journal of Clinical Endocrinology & Metabolism, 2006.
- Veldhuis JD, et al. "Joint mechanisms of impaired growth-hormone pulse renewal in aging men." Journal of Clinical Endocrinology & Metabolism, 2009.
- Anderson LL, et al. "Oral and parenteral administration of growth hormone-releasing peptides." Domestic Animal Endocrinology, 2001.
- Camanni F, et al. "Growth hormone-releasing peptides and their analogs." Frontiers in Neuroendocrinology, 1998.
Disclaimer
All products sold by PurposeLabs are intended for laboratory and research use only. They are not intended for human or animal consumption. The information provided is for educational purposes only and should not be construed as medical advice. Consult with qualified healthcare professionals for any health-related decisions.
CJC-1295 + Ipamorelin Blend is not approved by the TGA for therapeutic use in Australia. Products are sold strictly for research purposes in accordance with Australian regulations.